Good News – We Have Made It Over Another Funding Hurdle for the Department of Defense Medical Research Program for Fiscal 2013
Yesterday May 16, 2012, the House Appropriations Committee released their draft committee report to accompany the FY13 Defense Appropriations Act. This draft included the CDMRP requested budget for 2013. The good news is that the [...]
New Data Indicates That Provenge Works Best In Men With Lower PSA Scores
Today, May 16, 2012, Dendreon, the makers of Provenge, disclosed a new analysis of data of its pivotal 512-patient study of men with castrate resistant prostate cancer who received sipuleucel-T (Provenge). The new analysis separated [...]
GTx Receives clearance for New Capesaris Trials
GTx Inc. announced that FDA regulators will allow it to restart the clinical trials of its investigational prostate cancer drug Capesaris for men with castrate resistant advanced prostate cancer. They anticipate that the trials of [...]
Why Are Gays Excluded From Medical Research Studies?
For a reason that I can not figure out there are a small but still significant portion of medical studies that automatically exclude gays from participating without an apparent scientific reason. These studies usually have [...]
What Is The Actual Survival Advantage for Men Who Take Provenge? It’s Longer Than We Thought!
Understanding and deciding on appropriate treatments for men with advanced prostate cancer can be confusing. All the treatments come with side effects and one never knows what the benefits might be for an individual. Even [...]
Zytiga in High Doses and Zytiga Combined with MDV3100 Increase the Length of Response Time In Men with Advanced Prostate Cancer
According to recent trials led by The Institute of Cancer Research (ICR) (UK) and The Royal Marsden (UK) combining Zytiga (abiraterone acetate) with the yet FDA unapproved investigational drug MDV3100 could increase the number of [...]